Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

Development and Prospective Validation of a Multimodal Fusion Artificial Intelligence Model for Predicting the Efficacy of Neoadjuvant Treatment of Bladder Cancer

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

This study is a multi-center observational study without interventions, including the construction of an AI diagnostic model and retrospective testing of a multi-center cohort. The study participants are bladder cancer patients who have undergone imaging examinations, been pathologically diagnosed, and received neoadjuvant treatment, with complete clinical and pathological data. The study plans to enroll 130 patients from our center, collecting corresponding imaging images, and gathering clinical and genomic data to build and internally validate a multimodal AI model. The model's generalization and robustness will be tested to explore the association between multimodal data and the efficacy of neoadjuvant treatment for bladder cancer. The aim is to assist clinicians in predicting and evaluating the efficacy of neoadjuvant treatment for bladder cancer, with the goal of improving patient diagnosis, treatment outcomes, and prognosis.

Who May Be Eligible (Plain English)

Who May Qualify: - Bladder occupying lesions, with histopathological confirmation of bladder cancer after resection. - Planned neoadjuvant therapy and radical cystectomy. Who Should NOT Join This Trial: - Patients who have not undergone standard bladder imaging examinations or have missing imaging or pathological data. - Patients who have received local treatments (such as interventional embolization) or systemic treatments (such as radiotherapy, chemotherapy, immunotherapy, or targeted therapy). - Poor quality of imaging or pathological images. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Bladder occupying lesions, with histopathological confirmation of bladder cancer after resection. * Planned neoadjuvant therapy and radical cystectomy. Exclusion Criteria: * Patients who have not undergone standard bladder imaging examinations or have missing imaging or pathological data. * Patients who have received local treatments (such as interventional embolization) or systemic treatments (such as radiotherapy, chemotherapy, immunotherapy, or targeted therapy). * Poor quality of imaging or pathological images.

Treatments Being Tested

DIAGNOSTIC_TEST

Artificial intelligence (AI)-based diagnostic model

Collect magnetic resonance imaging and pathological slides of resected tumor of the enrolled patients. Analyze the data using the AI model to generate diagnostic results (sensitive or insensitive to the neoadjavant therapy). No intervention to patients would be performed in this diagnostic test study.

Locations (1)

Sun Yat-sen Memorial Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China